NUS vs STEK
NU Skin Enterprises, Inc. and Stemtech Corporation, side by side — 6 fiscal years reported in USD, drawn from SEC filings.
At a glance
Most recent reported year
| Metric | NUS | STEK |
|---|---|---|
| Revenue | $1.5B | $2.9M |
| Net income | $160.2M | $-4.0M |
| Gross margin | 69.4% | 80.3% |
| Net margin | 10.8% | −140.7% |
| Return on equity | 22.0% | — |
| Diluted EPS | $3.18 | −$0.02 |
| Dividend / share | $0.35 | — |
| Payout ratio | 7.4% | — |
| Free cash flow | $46.0M | $-483,583 |
| Equity | $805.2M | $-7.0M |
| Net debt / equity | −0.02× | — |
| Current ratio | 2.08× | 0.04× |
| Revenue CAGR 5y | −10.5% | −8.1% |
| Profit CAGR 5y | −3.5% | — |
NUS bills 516.3× the revenue of STEK, and STEK closed the last reported year at a loss.
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner.
Advertisement
AdSense · Leaderboard 728×90 · responsive
Revenue by year
6 years side by side
| Fiscal year | NUS | STEK |
|---|---|---|
| FY2025 | $1.5B | $2.9M |
| FY2024 | $1.7B | $5.1M |
| FY2023 | $2.0B | $4.9M |
| FY2022 | $2.2B | $4.6M |
| FY2021 | $2.7B | $4.3M |
| FY2020 | $2.6B | $4.4M |
Net income by year
Bottom line
| Fiscal year | NUS | STEK |
|---|---|---|
| FY2025 | $160.2M | $-4.0M |
| FY2024 | $-146.6M | $-3.8M |
| FY2023 | $8.6M | $-5.4M |
| FY2022 | $104.8M | $-8.5M |
| FY2021 | $147.3M | $-7.1M |
| FY2020 | $191.4M | $-916,697 |
Advertisement
AdSense · Rectangle 336×280